

PB 2 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 1)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 30th January 2025

REBECCA RICHARDSON

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division

Content	S		
	1	Name	1
	2	Commencement	1
	3	Authority	1
	4	Schedules	1
Schedule 1-	—Am	endments	2
	ional H 3 120 of	Tealth (Pharmaceutical benefits—early supply) Instrument 2015 (2015).	2

1 Name

- (1) This instrument is the *National Health (Pharmaceutical benefits early supply) Amendment Instrument 2025 (No. 1).*
- (2) This instrument may also be cited as PB 2 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information									
Column 1	Column 2	Column 3							
Provisions	Commencement	Date/Details							
1. The whole of this instrument	1 February 2025	1 February 2025							

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

- [1] Schedule 1, omit entry for Alirocumab
- [2] Schedule 1, after entry for Estradiol in the form Transdermal patches 390 micrograms, 8

insert:

	Transdermal patches 390 micrograms, 24 (S19A)	20	1	1						
[3] Sched	3] Schedule 1, entry for Niraparib									
omit:										
	Capsule 100 mg (as tosilate monohydrate)	20	56	2						
		20	56	5						
		20	84	2						
		20	84	5						
[4] Schedule 1, after entry for Selegiline										
insert:										
Selpercatinib	Capsule 40 mg	20	56	5						
	Capsule 80 mg	20	112	5						